Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer [Gastrointestinal Cancer]

Conclusion Regorafenib provides minimal incremental benefit at high incremental cost per QALY in the third-line management of metastatic colorectal cancer. The cost-effectiveness of regorafenib could be improved by the use of value-based pricing.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Chemotherapy, Cost Effectiveness Gastrointestinal Cancer Source Type: research